Literature DB >> 2539846

Glucocorticoid dependency as a prognostic factor in radiotherapy for cerebral gliomas.

M Hohwieler Schloss1, S R Freidberg, G J Heatley, T C Lo.   

Abstract

Records of 76 consecutive patients treated with radiotherapy for cerebral gliomas were reviewed. Eleven patients had no tissue diagnosis, and their outcome was comparable to that of patients with glioblastoma. Patients with other histologic diagnoses had much better results. Among the entire study population, the most important prognostic factors included age and histologic grade. Even with stratification by histologic grade and age, glucocorticoid (steroid) dependency was a reliable prognostic indicator in terms of survival. Fifteen of the 47 patients (32%) who were less steroid dependant are still alive with a median survival time of 29 months. Among the 29 patients who were heavily dependant on steroids during the course of radiotherapy, the median survival time was 5 months with only 2 patients (7%) still alive.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539846     DOI: 10.3109/02841868909111181

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  11 in total

1.  Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.

Authors:  Michael P Gustafson; Yi Lin; Kent C New; Peggy A Bulur; Brian Patrick O'Neill; Dennis A Gastineau; Allan B Dietz
Journal:  Neuro Oncol       Date:  2010-02-23       Impact factor: 12.300

Review 2.  Clinical Relevance of Steroid Use in Neuro-Oncology.

Authors:  K Ina Ly; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 3.  Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Authors:  Nils D Arvold; Terri S Armstrong; Katherine E Warren; Susan M Chang; Lisa M DeAngelis; Jaishri Blakeley; Marc C Chamberlain; Erin Dunbar; Herbert H Loong; David R Macdonald; David A Reardon; Michael A Vogelbaum; Ying Yuan; Michael Weller; Martin van den Bent; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

4.  Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.

Authors:  Yan Li; Janine M Lupo; Mei-Yin Polley; Jason C Crane; Wei Bian; Soonmee Cha; Susan Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2011-02-04       Impact factor: 12.300

5.  Impact of postoperative dexamethasone on survival, steroid dependency, and infections in newly diagnosed glioblastoma patients.

Authors:  Akshitkumar M Mistry; Sumeeth V Jonathan; Meredith A Monsour; Bret C Mobley; Stephen W Clark; Paul L Moots
Journal:  Neurooncol Pract       Date:  2021-06-23

6.  Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials.

Authors:  Kathryn A Carson; Stuart A Grossman; Joy D Fisher; Edward G Shaw
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Authors:  Suja Saraswathy; Forrest W Crawford; Kathleen R Lamborn; Andrea Pirzkall; Susan Chang; Soonmee Cha; Sarah J Nelson
Journal:  J Neurooncol       Date:  2008-09-23       Impact factor: 4.130

8.  Steroid management in newly diagnosed glioblastoma.

Authors:  Mariel B Deutsch; Katherine S Panageas; Andrew B Lassman; Lisa M Deangelis
Journal:  J Neurooncol       Date:  2013-03-06       Impact factor: 4.130

9.  Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma.

Authors:  Nader Pouratian; R Webster Crowley; Jonathan H Sherman; Jay Jagannathan; Jason P Sheehan
Journal:  J Neurooncol       Date:  2009-03-29       Impact factor: 4.130

10.  Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Authors:  Lisa B E Shields; Brent J Shelton; Andrew J Shearer; Li Chen; David A Sun; Sarah Parsons; T David Bourne; Renato LaRocca; Aaron C Spalding
Journal:  Radiat Oncol       Date:  2015-10-31       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.